Literature DB >> 17516690

Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.

Michael Kurowski1, Charles Oo, Hugh Wiltshire, Joanne Barrett.   

Abstract

Entities:  

Year:  2004        PMID： 17516690     DOI： 10.2165/00044011-200424010-00006

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  16 in total

1.  Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104.

Authors:  E J Eisenberg; A Bidgood; K C Cundy
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

2.  Impact of epidemic type A influenza in a defined adult population.

Authors:  W H Barker; J P Mullooly
Journal:  Am J Epidemiol       Date:  1980-12       Impact factor: 4.897

3.  Oral oseltamivir treatment of influenza in children.

Authors:  R J Whitley; F G Hayden; K S Reisinger; N Young; R Dutkowski; D Ipe; R G Mills; P Ward
Journal:  Pediatr Infect Dis J       Date:  2001-02       Impact factor: 2.129

4.  Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.

Authors:  H Wiltshire; B Wiltshire; A Citron; T Clarke; C Serpe; D Gray; W Herron
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-08-18

5.  Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

Authors:  J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

6.  Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

Authors:  K G Nicholson; F Y Aoki; A D Osterhaus; S Trottier; O Carewicz; C H Mercier; A Rode; N Kinnersley; P Ward
Journal:  Lancet       Date:  2000-05-27       Impact factor: 79.321

7.  Influenza A virus infection of human middle ear cells in vitro.

Authors:  C A Buchman; N Fregien
Journal:  Laryngoscope       Date:  2000-10       Impact factor: 3.325

8.  Effect of Streptococcus pneumoniae and influenza A virus on middle ear antimicrobial pharmacokinetics in experimental otitis media.

Authors:  G H Jossart; D M Canafax; G R Erdmann; M J Lovdahl; H Q Russlie; S K Juhn; G S Giebink
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

9.  Prevalence of various respiratory viruses in the middle ear during acute otitis media.

Authors:  T Heikkinen; M Thint; T Chonmaitree
Journal:  N Engl J Med       Date:  1999-01-28       Impact factor: 91.245

10.  Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza.

Authors:  D M Perrotta; M Decker; W P Glezen
Journal:  Am J Epidemiol       Date:  1985-09       Impact factor: 4.897
View more
  9 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 2.  Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.

Authors:  Brian E Davies
Journal:  J Antimicrob Chemother       Date:  2010-04       Impact factor: 5.790

3.  Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system.

Authors:  Gerhard Hoffmann; Christoph Funk; Stephen Fowler; Michael B Otteneder; Alexander Breidenbach; Craig R Rayner; Tom Chu; Eric P Prinssen
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

Review 4.  Safety and pharmacology of oseltamivir in clinical use.

Authors:  Regina Dutkowski; Bharat Thakrar; Enrico Froehlich; Pia Suter; Charles Oo; Penny Ward
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

5.  A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses.

Authors:  Vanessa Escuret; Patrick J Collins; Jean-Sébastien Casalegno; Sebastien G Vachieri; Nicholas Cattle; Olivier Ferraris; Murielle Sabatier; Emilie Frobert; Valérie Caro; John J Skehel; Steve Gamblin; Frédéric Valla; Martine Valette; Michèle Ottmann; John W McCauley; Rodney S Daniels; Bruno Lina
Journal:  J Infect Dis       Date:  2014-05-03       Impact factor: 5.226

6.  Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial.

Authors:  Nila J Dharan; Alicia M Fry; Burney A Kieke; Laura Coleman; Jennifer Meece; Mary Vandermause; Larisa V Gubareva; Alexander I Klimov; Edward A Belongia
Journal:  Influenza Other Respir Viruses       Date:  2011-11-26       Impact factor: 4.380

Review 7.  Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.

Authors:  James R Smith; Craig R Rayner; Barbara Donner; Martina Wollenhaupt; Klaus Klumpp; Regina Dutkowski
Journal:  Adv Ther       Date:  2011-11-01       Impact factor: 3.845

8.  A physiologically-based pharmacokinetic model of oseltamivir phosphate and its carboxylate metabolite for rats and humans.

Authors:  Guanghua Gao; Francis Law; Ricky Ngok Shun Wong; Nai Ki Mak; Mildred Sze Ming Yang
Journal:  ADMET DMPK       Date:  2019-02-23

Review 9.  Antivirals for the treatment and prevention of epidemic and pandemic influenza.

Authors:  John S Oxford
Journal:  Influenza Other Respir Viruses       Date:  2007-01       Impact factor: 4.380
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.